BerGenBio ASA (BRRGD) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BerGenBio ASA, a Norwegian biopharmaceutical company, has successfully completed a reverse share split at a ratio of 100:1, resulting in a new share capital structure with 39,087,116 shares valued at NOK 10 each. The company, listed on the Oslo Stock Exchange under the ticker BGBIO, is advancing its lead candidate bemcentinib, targeting AXL for the treatment of aggressive diseases including certain cancers and severe respiratory infections.
For further insights into BRRGD stock, check out TipRanks’ Stock Analysis page.